Skip to content
Reprogramming Immunity:  How CCR5 Blockade Could Redefine Cancer Therapy episode artwork

Oct 14, 2025 29 min

Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

from Rx for Biotech Hosted by Podcast Host Christopher Leidli

In this podcast episode, Dr. Jay Lalezari, CEO of CytoDyn Therapeutics, discusses the company's progress in developing a novel immunotherapy that targets the CCR5 receptor, one of the master immune cell regulators. Jay reviews some of the early clinical data with leronlimab, a first-in-class investigational monocolonal antibody that targets the CCR5 receptor and is being studied in metasatic triple-negative breast cancer and colorectal cancer.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Reprogramming Immunity: How CCR5 Blockade Could Redefine Cancer Therapy

0:00 29:00

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Rx for Biotech?

This episode is 29 minutes long.

When was this Rx for Biotech episode published?

This episode was published on October 14, 2025.

Can I download this Rx for Biotech episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.